Evaluating the Measurement Properties of the Self-Assessment of Treatment Version II, Follow-Up Version, in Patients with Painful Diabetic Peripheral Neuropathy

Table 2

Test-retest reliability of SAT II follow-up scores among stable subjects (EQ-5D VAS < 20% and BPI-DN item 5 < 20%): week 8 to week 12.

SAT II domains	EQ-5D VAS < 20%					BPI-DN item 5 < 20%
		Mean (SD) week 8	Mean (SD) week 12				Mean (SD) week 8	Mean (SD) week 12	Difference	ICC
Pain improvement	253	1.34 (1.36)	1.18 (1.41)	−0.16	0.73	213	0.98 (1.20)	0.86 (1.22)	−0.11	0.78
Impact summary	247	1.14 (1.25)	1.07 (1.28)	−0.08	0.79	209	0.87 (1.06)	0.80 (1.09)	−0.07	0.75
Treatment continuation	246	2.78 (1.25)	2.65 (1.36)	−0.13	0.72	207	2.62 (1.25)	2.35 (1.40)	−0.27	0.62
Treatment comparison	244	2.69 (0.92)	2.58 (0.98)	−0.11	0.68	205	2.50 (0.85)	2.40 (0.95)	−0.09	0.68

Stable defined as <20% change on EQ-5D VAS score from week 8 to week 12.
Stable defined as <20% change on BPI-DN item 5 from week 8 to week 12.
Difference = week 12 mean − week 8 mean.
Intraclass correlation coefficient.